350 related articles for article (PubMed ID: 33707082)
1. Updates in adrenal steroidogenesis inhibitors for Cushing's syndrome - A practical guide.
Varlamov EV; Han AJ; Fleseriu M
Best Pract Res Clin Endocrinol Metab; 2021 Jan; 35(1):101490. PubMed ID: 33707082
[TBL] [Abstract][Full Text] [Related]
2. Approach to the Patient Treated with Steroidogenesis Inhibitors.
Castinetti F; Nieman LK; Reincke M; Newell-Price J
J Clin Endocrinol Metab; 2021 Jun; 106(7):2114-2123. PubMed ID: 33675650
[TBL] [Abstract][Full Text] [Related]
3. Cushing's disease: adrenal steroidogenesis inhibitors.
Pivonello R; Simeoli C; Di Paola N; Colao A
Pituitary; 2022 Oct; 25(5):726-732. PubMed ID: 36036308
[TBL] [Abstract][Full Text] [Related]
4. Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies.
Fleseriu M; Castinetti F
Pituitary; 2016 Dec; 19(6):643-653. PubMed ID: 27600150
[TBL] [Abstract][Full Text] [Related]
5. Osilodrostat Is a Potential Novel Steroidogenesis Inhibitor for the Treatment of Cushing Syndrome: An In Vitro Study.
Creemers SG; Feelders RA; de Jong FH; Franssen GJH; de Rijke YB; van Koetsveld PM; Hofland LJ
J Clin Endocrinol Metab; 2019 Aug; 104(8):3437-3449. PubMed ID: 31127821
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
[TBL] [Abstract][Full Text] [Related]
7. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors.
Engelhardt D; Weber MM
J Steroid Biochem Mol Biol; 1994 Jun; 49(4-6):261-7. PubMed ID: 8043488
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Cushing's syndrome with osilodrostat: practical applications of recent studies with case examples.
Fleseriu M; Biller BMK
Pituitary; 2022 Dec; 25(6):795-809. PubMed ID: 36002784
[TBL] [Abstract][Full Text] [Related]
9. Adrenally Directed Medical Therapies for Cushing Syndrome.
Tritos NA
J Clin Endocrinol Metab; 2021 Jan; 106(1):16-25. PubMed ID: 33118025
[TBL] [Abstract][Full Text] [Related]
10. Clinical Utility of Osilodrostat in Cushing's Disease: Review of Currently Available Literature.
Perosevic M; Tritos NA
Drug Des Devel Ther; 2023; 17():1303-1312. PubMed ID: 37143705
[TBL] [Abstract][Full Text] [Related]
11. Medical treatment of Cushing's syndrome: adrenal-blocking drugs and ketaconazole.
Feelders RA; Hofland LJ; de Herder WW
Neuroendocrinology; 2010; 92 Suppl 1():111-5. PubMed ID: 20829630
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease.
Tanaka T; Satoh F; Ujihara M; Midorikawa S; Kaneko T; Takeda T; Suzuki A; Sato M; Shimatsu A
Endocr J; 2020 Aug; 67(8):841-852. PubMed ID: 32378529
[TBL] [Abstract][Full Text] [Related]
13. What is the role of medical therapy in adrenal-dependent Cushing's syndrome?
Braun LT; Reincke M
Best Pract Res Clin Endocrinol Metab; 2020 May; 34(3):101376. PubMed ID: 32063487
[TBL] [Abstract][Full Text] [Related]
14. Osilodrostat (Isturisa) for Cushing's disease.
Med Lett Drugs Ther; 2021 Feb; 63(1617):21-23. PubMed ID: 33647005
[No Abstract] [Full Text] [Related]
15. Osilodrostat oral tablets for adults with Cushing's disease.
Martino M; Aboud N; Lucchetti B; Salvio G; Arnaldi G
Expert Rev Endocrinol Metab; 2022 Mar; 17(2):99-109. PubMed ID: 35220871
[TBL] [Abstract][Full Text] [Related]
16. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome.
Kamenický P; Droumaguet C; Salenave S; Blanchard A; Jublanc C; Gautier JF; Brailly-Tabard S; Leboulleux S; Schlumberger M; Baudin E; Chanson P; Young J
J Clin Endocrinol Metab; 2011 Sep; 96(9):2796-804. PubMed ID: 21752886
[TBL] [Abstract][Full Text] [Related]
17. Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing's Syndrome: Results From a Single Center Cohort Study.
Detomas M; Altieri B; Deutschbein T; Fassnacht M; Dischinger U
Front Endocrinol (Lausanne); 2022; 13():903545. PubMed ID: 35769081
[TBL] [Abstract][Full Text] [Related]
18. A polymorphism in the CYP17A1 gene influences the therapeutic response to steroidogenesis inhibitors in Cushing's syndrome.
Valassi E; Aulinas A; Glad CA; Johannsson G; Ragnarsson O; Webb SM
Clin Endocrinol (Oxf); 2017 Nov; 87(5):433-439. PubMed ID: 28665508
[TBL] [Abstract][Full Text] [Related]
19. Drugs in the medical treatment of Cushing's syndrome.
Schteingart DE
Expert Opin Emerg Drugs; 2009 Dec; 14(4):661-71. PubMed ID: 19939210
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients.
Daniel E; Aylwin S; Mustafa O; Ball S; Munir A; Boelaert K; Chortis V; Cuthbertson DJ; Daousi C; Rajeev SP; Davis J; Cheer K; Drake W; Gunganah K; Grossman A; Gurnell M; Powlson AS; Karavitaki N; Huguet I; Kearney T; Mohit K; Meeran K; Hill N; Rees A; Lansdown AJ; Trainer PJ; Minder AE; Newell-Price J
J Clin Endocrinol Metab; 2015 Nov; 100(11):4146-54. PubMed ID: 26353009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
